Embla Medical's brands include Össur, a global prosthetics and bracing provider, FIOR & GENTZ, a neuro orthotics developer, and College Park, a customized prosthetics provider. The company's Growth'27 strategy focuses on expanding mobility solutions, specifically in Patient Reach, Innovative Solutions and Orthotic and Prosthetic Value Creation as well as Bracing Simplified. The company combines innovation with a global patient care network to deliver comprehensive orthopedic and mobility solutions.
Cyborg Score Rationale
Q3 2025 results showed acceleration compared to the first half of the year and exceeded analyst expectations on both top and bottom lines. The company maintains strong market position with extensive global operations and consistent innovation, though medical device markets face regulatory headwinds. Recent share buyback activity demonstrates management confidence.
Top Insights
Embla Medical has produced 2,100 patents and 650 trademarks, significantly strengthening the Orthotic and Prosthetic Industry.
Shares are listed on the NASDAQ Copenhagen Stock Exchange.
In 2023, Össur, a subsidiary of Embla Medical, opened a global innovation center in Reykjavik.
Recent activity includes December 2025 share buyback program initiation and November 2025 expansion of support for Ukrainian amputees with Kyiv clinic.
Named Competitors
Integrated Orthopedic Solutions — Medical device and surgical solutions provider
Orthopedic Implants & Devices — Surgical equipment and orthopedic implants
Lower Limb Prosthetics — Orthopedic and musculoskeletal solutions
Recent Developments
(January 2026) Initiated new share buyback program targeting capital reduction
(November 2025) Expanded support for Ukrainian amputees with Kyiv clinic partnership